Related Experiment Videos
The hypoxic cell sensitizer programme in the United States
The British Journal of Cancer. Supplement
|June 1, 1978
Summary
Misonidazole, a potential radiosensitizer, was evaluated in a Phase I trial. Initial results show acceptable safety with mild peripheral neuropathy in one patient, warranting further investigation in cancer treatment.
Area of Science:
- Oncology
- Radiotherapy
- Pharmacology
Background:
- Misonidazole is investigated as a radiosensitizer to enhance cancer treatment efficacy.
- The U.S. National Cancer Institute is actively developing novel radiosensitizer agents.
- Phase I clinical trials are crucial for initial safety and dosage evaluation of new drugs.
Purpose of the Study:
- To describe the initial results of a Phase I clinical trial of misonidazole.
- To evaluate the safety and tolerability of misonidazole in cancer patients.
- To assess the pharmacokinetic profile of misonidazole, including serum levels and urinary excretion.
Main Methods:
- A Phase I clinical trial involving 12 patients.
- Administration of misonidazole in doses ranging from 1 to 2 g/m2 over 1 to 6 doses.
- Monitoring of serum drug levels at 4-6 hours post-administration.
- Analysis of urinary excretion using High-Performance Liquid Chromatography (HPLC).
Main Results:
- Serum misonidazole levels ranged from 25-87 microgram/ml at 4-6 hours.
- One patient experienced mild peripheral neuropathy, indicating a manageable side effect profile.
- The primary route of urinary excretion was a demethylated metabolite.
Conclusions:
- Misonidazole demonstrates preliminary safety in a Phase I evaluation.
- The observed pharmacokinetic profile and side effects support further clinical investigation.
- Misonidazole's role as a radiosensitizer in cancer therapy requires continued research.